ARCHIVES

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

Environmental Emphasis Urged, Including New Role For Comp Centers NCAB Unenthusiastic

March 21, 1975

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

In Brief: DeVita wins $150,000 Pezcoller Prize; BreastPac To “Storm” Capitol On Bastille Day For More $$

July 8, 1988

In Brief: William Roper To Head Health Research Center; Announcement Of New NIH director Is Imminent

July 2, 1993

Dugan Head ACCC, Yarbro President Elects; Amos Honored

March 18, 1983

“Inoperable” Prostate Cancer May Be Operable, Curable

April 29, 2005